|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We evaluated if BCLP mRNA detection in the blood is useful in gynecologic malignancies.
|
11724320 |
2001 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We demonstrated that CAC1 is over-expressed in malignant tumors, and cellular CAC1 depletion resulted in cancer growth suppression.
|
22903020 |
2012 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Via a 14;18 chromosomal translocation, BCLP is overexpressed in most follicular lymphomas as well as some other non-Hodgkin's lymphomas, and it has also been documented in other nonlymphomatous malignancies.
|
7590697 |
1995 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Compared to CAC = 0, individuals with CAC 1-10 had an increased multivariable-adjusted risk of CVD death only under age 40.
|
31784032 |
2020 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Cox models were used to obtain hazard ratios according to CAC category, or per 1 SD log2[CAC+1], adjusted for vascular risk factor, APOE-ε4, with or without exclusion of interim stroke or cardiovascular disease.
|
28465455 |
2017 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
We noted a significantly increased risk of CHD [hazard ratio (HR): 2.6 (1.5-4.3)] and CVD [HR: 2.3 (1.8-2.9)] mortality per unit increase in In (CAC + 1).
|
31486775 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results suggested that an increase in Tmem54 and Cd74 expression via DNA methylation reduction was involved in the tumor increase in the F2 male offspring by gestational arsenite exposure of F0 females.
|
31215104 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that BCLP might be associated with cell morphology and a regulation of growth pattern of tumor.
|
11394883 |
2001 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We conclude that miR-199a-5p can regulate CAC1 and function as a tumor suppressor in colorectal cancer.
|
22903020 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Compared to participants with CAC = 0, the SHR for CVD mortality was 1.44 [95% confidence interval (CI) 1.14-1.81], 2.26 (95% CI 1.76-2.90), and 3.68 (95% CI 2.90-4.67) for patients with CAC 1-99, 100-299, and ≥300, and the SHR for cancer was 1.04 (95% CI 0.88-1.23), 1.19 (95% CI 0.98-1.46), and 1.30 (95% CI 1.07-1.58).
|
30590498 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Human database analysis using the Cancer Genome Atlas indicated that TMEM54, CD74, and TRIB3 were significantly increased and that ATOH8 was decreased in hepatocellular carcinoma.
|
31215104 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
CAC1 is highly expressed in cancer tissues and cancer cell lines.
|
19829063 |
2009 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
|
31504073 |
2019 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We further identified CAC1, a cell cycle-related protein expressed in colorectal cancer, as a miR-199a-5p target.
|
22903020 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
|
31504073 |
2019 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
BCLP was detected in 47 of 126 cases (37%) including 32 AC (44%), 10 SCC 925%), two ASC (40%), and three LCC (38%).
|
7590697 |
1995 |
|
Alzheimer's Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our findings showed that the expression level of CAC1 in the hippocampus of AD patients was significantly lower than that of normal controls.
|
22415352 |
2012 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, our study provides the first evidence that CAC1, associated with LSD1, functions as an ERα corepressor, implicating a potential antitumor target in ERα-positive breast cancer.
|
23178685 |
2013 |
|
Malignant tumor of cervix
|
0.010 |
Biomarker
|
disease |
BEFREE |
Beta-casein-like protein (BCLP) is a putative protein on cervical cancer and exhibits immunological characteristics similar to those of bovine beta-casein.
|
11724320 |
2001 |
|
Cleft Palate
|
0.010 |
Biomarker
|
disease |
BEFREE |
More than half (55%, n = 36) were isolated cleft palates, and 35% (n = 23) were BCLPs.
|
29437500 |
2018 |